DOCSLIB.ORG

Assessment Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Assessment Report 21 April 2017 EMA/31226/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Brineura International non-proprietary name: cerliponase alfa Procedure No. EMEA/H/C/004065/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 9 2.1. Problem statement ............................................................................................... 9 2.1.1. Disease or condition .......................................................................................... 9 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features, aetiology and pathogenesis ....................................................... 9 2.1.4. Clinical presentation, diagnosis and stage/prognosis ............................................ 10 2.1.5. Management ................................................................................................... 10 2.2. About the product .............................................................................................. 10 2.3. Quality aspects .................................................................................................. 11 2.3.1. Introduction.................................................................................................... 11 2.4. Active Substance ............................................................................................... 11 2.4.1. Finished Medicinal Product ................................................................................ 14 2.4.2. Discussion on chemical, pharmaceutical and biological aspects.............................. 17 2.4.3. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 17 2.4.4. Recommendation(s) for future quality development ............................................. 18 2.5. Non-clinical aspects ............................................................................................ 18 2.5.1. Introduction.................................................................................................... 18 2.5.2. Pharmacology ................................................................................................. 18 2.5.3. Pharmacokinetics ............................................................................................ 19 2.5.4. Toxicology ...................................................................................................... 20 2.5.5. Ecotoxicity/environmental risk assessment ......................................................... 21 2.5.6. Discussion on non-clinical aspects ..................................................................... 21 2.5.7. Conclusion on the non-clinical aspects ............................................................... 23 2.6. Clinical aspects .................................................................................................. 23 2.6.1. Introduction.................................................................................................... 23 2.6.2. Pharmacokinetics ............................................................................................ 24 2.6.3. Pharmacodynamics .......................................................................................... 25 2.6.4. Discussion on clinical pharmacology ................................................................... 26 2.6.5. Conclusions on clinical pharmacology ................................................................. 26 2.7. Clinical efficacy .................................................................................................. 27 2.7.1. Dose response study........................................................................................ 27 2.7.2. Main study ..................................................................................................... 27 2.7.3. Discussion on clinical efficacy ............................................................................ 57 2.7.4. Conclusions on the clinical efficacy .................................................................... 63 2.8. Clinical safety .................................................................................................... 64 2.8.1. Discussion on clinical safety .............................................................................. 72 2.8.2. Conclusions on the clinical safety ...................................................................... 76 2.9. Risk Management Plan ........................................................................................ 77 Assessment report EMA/312226/2017 Page 2/95 2.10. Pharmacovigilance ............................................................................................ 79 2.11. New Active Substance ....................................................................................... 79 2.12. Product information .......................................................................................... 79 2.12.1. User consultation ........................................................................................... 79 2.12.2. Labelling exemptions ..................................................................................... 79 2.12.3. Additional monitoring ..................................................................................... 79 3. Benefit-Risk Balance ............................................................................. 80 3.1. Therapeutic Context ........................................................................................... 80 3.1.1. Disease or condition ........................................................................................ 80 3.1.2. Available therapies and unmet medical need ....................................................... 80 3.1.3. Main clinical studies ......................................................................................... 80 3.2. Favourable effects .............................................................................................. 81 3.3. Uncertainties and limitations about favourable effects ............................................. 82 3.4. Unfavourable effects ........................................................................................... 83 3.5. Uncertainties and limitations about unfavourable effects ......................................... 84 3.6. Effects Table ...................................................................................................... 85 3.7. Benefit-risk assessment and discussion ................................................................. 89 3.7.1. Importance of favourable and unfavourable effects .............................................. 89 3.7.2. Balance of benefits and risks ............................................................................ 90 3.7.3. Additional considerations on the benefit-risk balance ........................................... 90 3.8. Conclusions ....................................................................................................... 91 4. Recommendations ................................................................................. 91 Assessment report EMA/312226/2017 Page 3/95 List of abbreviations ADA Anti-drug antibodies ADE Acceptable daily exposure AE Adverse event API Active pharmaceutical ingredient BBB Blood brain barrier BMN 190 Recombinant human tripeptidyl peptidase-1 CE-LIF Capillary electrophoresis with laser induced fluorescence CFS Cerebrospinal fluid CHO Chinese Hamster Ovary CHOP CHO proteins, host cell proteins CI-M6PR Cation-independent mannose-6-phosphate receptor CLN2 Classical late infantile CLN2, cLINCL, or Jansky-Bielschowsky disease CQA Critical quality attributes CRF Case report form CSF Cerebrospinal fluid CSR Clinical study report CT Computed tomography CTCAE Common Terminology Criteria for Adverse Events CZE-LIF Capillary Zone Electrophoresis/Laser-Induced Fluorescence Detection DBP Diastolic blood pressure DMC Data Monitoring Committee DP Drug product DS Drug substance EOPC End of Production Cells ERT Enzyme replacement therapy FBDS Formulated bulk drug substance FS Flushing solution HCCF Harvested cell culture fluid HIC Hydrophobic interaction chromatography HIPAA Health Insurance Portability and Accountability Act HTST High-Temperature-Short-Time ICF Informed consent form ICV Intracerebroventricular IEC Independent Ethics Committee IgE Immunoglobulin E ICP-MS Inductively coupled plasma mass spectrometry ICP-OES Inductively coupled plasma optical emission spectrometry IM Intramuscular IND Investigational New Drug (application) IRB Institutional Review Board cIEF Capillary Isoelectric Focusing IT-C Intrathecal-cisternal IT-L Intrathecal-lumbar ITT Intent-to-treat IVC Intracerebroventricularly LCA Limit of in vitro cell age Assessment report EMA/312226/2017
Load more

Recommended publications
  • Exploiting Toxin Internalization Receptors to Enhance Delivery of Proteins to Lysosomes for Enzyme Replacement Therapy
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.22.915298; this version posted January 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Exploiting toxin internalization receptors to enhance delivery of proteins to lysosomes for enzyme replacement therapy Seiji N. Sugiman-Marangos1, Greg L. Beilhartz1, Xiaochu Zhao2, Dongxia Zhou3, Rong Hua3,4, Peter K. Kim3,4, James M. Rini3,5, Berge A. Minassian2,6, Roman A. Melnyk1,3 1Molecular Medicine Program, The Hospital for Sick Children Research Institute, 686 Bay Street Toronto, ON, Canada, M5G 0A4; 2Department of Pediatrics, The Hospital for Sick Children Research Institute, 686 Bay Street Toronto, ON, Canada, M5G 0A4;3Department of Biochemistry, University of Toronto, Toronto, ON, 1 King's College Circle, Canada M5S1A8; 4Cell Biology Program, The Hospital for Sick Children Research Institute, 686 Bay Street Toronto, ON, Canada, M5G 0A4; 5Department of Molecular Genetics, University of Toronto, ON, 1 King's College Circle, Canada M5S1A8; 6Department of Pediatrics and Dallas Children's Medical Center, University of Texas Southwestern, Dallas, Texas, USA 75390-9063; *Corresponding author: Roman A. Melnyk Associate Professor of Biochemistry and Senior Scientist University of Toronto and The Hospital for Sick Children, 686 Bay Street, Toronto, ON M5G 0A4 416-813-7654 x328557 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.22.915298; this version posted January 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses
    CNS Drugs (2019) 33:315–325 https://doi.org/10.1007/s40263-019-00620-8 LEADING ARTICLE Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses Alfried Kohlschütter1 · Angela Schulz1 · Udo Bartsch2 · Stephan Storch3 Published online: 15 March 2019 © The Author(s) 2019 Abstract The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by muta‑ tions in at least 13 diferent genes and primarily afect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epilepsy, loss of vision, motor disturbances, and early death. While various therapeutic strategies are currently being explored as treatment options for these fatal disorders, there is presently only one clinically approved drug that has been shown to efectively attenuate the progression of a specifc form of neuronal ceroid lipofuscinosis, CLN2 disease (cerliponase alfa, a lysosomal enzyme infused into the brain ventricles of patients with CLN2 disease). Therapeutic approaches for the treatment of other forms of neuronal ceroid lipofuscinosis include the administration of immunosuppressive agents to antagonize neuroinfammation associated with neurodegenera‑ tion, the use of various small molecules, stem cell therapy, and gene therapy. An important aspect of future work aimed at developing therapies for neuronal ceroid lipofuscinoses is the need for treatments that efectively attenuate neurodegenera‑ tion in both the brain and the retina.
    [Show full text]
  • Lysosomal Enzyme Tripeptidyl Peptidase 1 Plays a Role in Degradation of Beta Amyloid Fibrils
    bioRxiv preprint doi: https://doi.org/10.1101/639682; this version posted May 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Lysosomal enzyme tripeptidyl peptidase 1 plays a role in degradation of beta amyloid fibrils Abbreviated Title: TPP1 role in Aβ fibril degradation Dana Cruz1, Mukarram El-Banna2, Amitabha Majumdar1, David E. Sleat2, Michelle Muldowney1, Peter Lobel2&, Frederick R. Maxfield1& 1 Department of Biochemistry, Weill Cornell Medical College, New York, NY 10065. 2Center for Advanced Biotechnology and Medicine, Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854. &To whom correspondence should be addressed: Frederick R. Maxfield Weill Cornell Medical College Department of Biochemistry 1300 York Avenue New York, NY 10065 Tel: (646) 962-2759 Fax: (646) 962-0519 Email: [email protected] Peter Lobel Center for Advanced Biotechnology and Medicine Rutgers University 679 Hoes Lane Piscataway, NJ 08854 Tel: (848) 445-9831 Fax: (732) 235-5083 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/639682; this version posted May 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Alzheimer’s disease (AD) is characterized by the accumulation of amyloid plaques surrounded by microglia. In cell culture, microglia internalize fibrillar β-amyloid but do not degrade it efficiently. Unactivated microglia have a relatively high lysosomal pH, which impairs the activity of lysosomal proteases.
    [Show full text]
  • ISSN 1096-7192 Volume 126 , Issue 2 , February 2019
    ISSN 1096-7192 Volume 126 , Issue 2 , February 2019 Available online at www.sciencedirect.com Molecular Genetics and Metabolism 126 (2019) S1 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Program and Abstracts WORLDSymposium 2019* 15th Annual Research Meeting Hyatt Regency Orlando 9801 International Drive, Orlando, Florida, USA February 4 – 7, 2019 Organizing Committee Chester B. Whitley, PhD, MD, Chair Lalitha R. Belur, PhD** Philip J. Brooks, PhD** Amber R. Brown, CPP Brenda M. Diethelm-Okita, MPA Yoshikatsu Eto, MD, PhD** Amy Gaviglio, MS, LCGC** Stephen C. Groft, PharmD** Jeanine R. Jarnes, PharmD Priya S. Kishnani, MD, MBBS** Walter C. Low, PhD** R. Scott McIvor, PhD** Jill A. Morris, PhD** Li Ou, PhD** Anne R. Pariser, MD** Marc C. Patterson, MD** David A. Pearce, PhD** Mark S. Sands, PhD** Dawn C. Saterdalen, RN, MBA Danilo A. Tagle, PhD** Cynthia J. Tifft, MD, PhD** Tiina K. Urv, PhD** Steven U. Walkley, DVM, PhD * WORLD is the acronym for We’re Organizing Research for Lysosomal Diseases ** Special thanks is given to members of the Program Committee responsible for abstract review and scoring for platform presentation. https://doi.org/10.1016/j.ymgme.2018.12.013 Available online 29 December 2018 1096-7192 Molecular Genetics and Metabolism 126 (2019) S2–S6 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme WORLDSymposium™ 2019 Introduction Overview category of Basic Science was expanded to include 2 new subcategories: 1) Disease Mechanisms, Pathology, and Biomarkers of Lysosomal Now in the 15th year, WORLDSymposium™ is celebrating numerous Diseases, and 2) Developing Therapeutic Approaches for Lysosomal milestones in research for lysosomal diseases.
    [Show full text]
  • Therapeutic Landscape for Batten Disease: Current Treatments and Future Prospects
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Rev Manuscript Author Neurol. Author Manuscript Author manuscript; available in PMC 2019 August 05. Published in final edited form as: Nat Rev Neurol. 2019 March ; 15(3): 161–178. doi:10.1038/s41582-019-0138-8. Therapeutic landscape for Batten disease: current treatments and future prospects Tyler B. Johnson1, Jacob T. Cain1, Katherine A. White1, Denia Ramirez-Montealegre2, David A. Pearce1,3,*, Jill M. Weimer1,3,* 1Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA. 2Cole Neuroscience Center, University of Tennessee Medical Center, Knoxville, TN, USA. 3Department of Pediatrics, Sanford School of Medicine at the University of South Dakota, Sioux Falls, SD, USA. Abstract Batten disease (also known as neuronal ceroid lipofuscinoses) constitutes a family of devastating lysosomal storage disorders that collectively represent the most common inherited paediatric neurodegenerative disorders worldwide. Batten disease can result from mutations in 1 of 13 genes. These mutations lead to a group of diseases with loosely overlapping symptoms and pathology. Phenotypically, patients with Batten disease have visual impairment and blindness, cognitive and motor decline, seizures and premature death. Pathologically, Batten disease is characterized by lysosomal accumulation of autofluorescent storage material, glial reactivity and neuronal loss. Substantial progress has been made towards the development of effective therapies and treatments for the multiple forms of Batten disease. In 2017, cerliponase alfa (Brineura), a tripeptidyl peptidase enzyme replacement therapy, became the first globally approved treatment for CLN2 Batten disease. Here, we provide an overview of the promising therapeutic avenues for Batten disease, highlighting current FDA-approved clinical trials and prospective future treatments.
    [Show full text]
  • Missense Variation in TPP1 Gene Causes Neuronal Ceroid Lipofuscinosis Type 2 in a Family from Jammu and Kashmir-India
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 29 July 2021 doi:10.20944/preprints202107.0661.v1 Missense Variation in TPP1 Gene causes Neuronal Ceroid Lipofuscinosis Type 2 in a Family from Jammu and Kashmir-India Arshia Angural1, Kalaiarasan Ponnusamy2, Diksha Langeh1,#, Mamta Kumari1,#, Akshi Spolia1, #, Ekta Rai1, Ankush Sharma3, Kamal Kishore Pandita4,*, Swarkar Sharma1,* 1Human Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Kakryal, Jammu and Kashmir, India 2School of Biotechnology, Jawaharlal Nehru University, New Delhi, India 3Senior Consultant, Department of Neurology, Shri Mata Vaishno Devi Narayana Superspeciality Hospital, Kakryal, Jammu and Kashmir, India 4Independent Researcher, Health Clinic, Swam Vihar, Muthi, Jammu, Jammu and Kashmir, India #Equal contribution *Corresponding authors: Swarkar Sharma, email: [email protected], and Kamal Kishore Pandita, email: [email protected] ABSTRACT We report diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), a rare, hereditary neurodegenerative disease of childhood, in a four and a half year old girl, the first child of non- consanguineous parents with no family history. Despite extensive efforts by the parents, her clinical condition remained undiagnosed and without management, until recently. Our published “Bottom-up Approach”, based on comprehensive and multidisciplinary clinical, pathological, radiographical and genetic evaluations, played key role in diagnosis of the disease. Detailed analyses involving Next Generation Sequencing confirmed a missense variation NC_00011.10:g.6616374C>T (NP_000382.3:p.Arg339Gln; rs765380155) in exon 8 of TPP1 gene. In silico analyses predicted it to be highly pathogenic. Further family screening (including her both unaffected parents and asymptomatic, one year old younger sister) of the identified variation through Sanger Sequencing, revealed a perfect autosomal recessive segregation in the family.
    [Show full text]
  • Emerging New Roles of the Lysosome and Neuronal Ceroid Lipofuscinoses Anil B
    Mukherjee et al. Molecular Neurodegeneration (2019) 14:4 https://doi.org/10.1186/s13024-018-0300-6 REVIEW Open Access Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses Anil B. Mukherjee1* , Abhilash P. Appu1, Tamal Sadhukhan1, Sydney Casey1, Avisek Mondal1, Zhongjian Zhang1,2 and Maria B. Bagh1* Abstract Neuronal Ceroid Lipofuscinoses (NCLs), commonly known as Batten disease, constitute a group of the most prevalent neurodegenerative lysosomal storage disorders (LSDs). Mutations in at least 13 different genes (called CLNs) cause various forms of NCLs. Clinically, the NCLs manifest early impairment of vision, progressive decline in cognitive and motor functions, seizures and a shortened lifespan. At the cellular level, all NCLs show intracellular accumulation of autofluorescent material (called ceroid) and progressive neuron loss. Despite intense studies the normal physiological functions of each of the CLN genes remain poorly understood. Consequently, the development of mechanism-based therapeutic strategies remains challenging. Endolysosomal dysfunction contributes to pathogenesis of virtually all LSDs. Studies within the past decade have drastically changed the notion that the lysosomes are merely the terminal degradative organelles. The emerging new roles of the lysosome include its central role in nutrient-dependent signal transduction regulating metabolism and cellular proliferation or quiescence. In this review, we first provide a brief overview of the endolysosomal and autophagic pathways, lysosomal acidification and endosome-lysosome and autophagosome-lysosome fusions. We emphasize the importance of these processes as their dysregulation leads to pathogenesis of many LSDs including the NCLs. We also describe what is currently known about each of the 13 CLN genes and their products and how understanding the emerging new roles of the lysosome may clarify the underlying pathogenic mechanisms of the NCLs.
    [Show full text]
  • Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofu
    www.nature.com/scientificreports OPEN Untargeted Metabolite Profling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Received: 7 June 2018 Accepted: 12 September 2018 Late Infantile Neuronal Ceroid Published: xx xx xxxx Lipofuscinosis (CLN2, Batten Disease) Miriam Sindelar1, Jonathan P. Dyke 2, Ruba S. Deeb3, Dolan Sondhi3, Stephen M. Kaminsky3, Barry E. Kosofsky4, Douglas J. Ballon2,3, Ronald G. Crystal3 & Steven S. Gross1 Late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a rare lysosomal storage disorder caused by a monogenetic defciency of tripeptidyl peptidase-1 (TPP1). Despite knowledge that lipofuscin is the hallmark disease product, the relevant TPP1 substrate and its role in neuronal physiology/pathology is unknown. We hypothesized that untargeted metabolite profling of cerebrospinal fuid (CSF) could be used as an efective tool to identify disease-associated metabolic disruptions in CLN2 disease, ofering the potential to identify biomarkers that inform on disease severity and progression. Accordingly, a mass spectrometry-based untargeted metabolite profling approach was employed to diferentiate CSF from normal vs. CLN2 defcient individuals. Of 1,433 metabolite features surveyed, 29 linearly correlated with currently employed disease severity scores. With tandem mass spectrometry 8 distinct metabolite identities were structurally confrmed based on retention time and fragmentation pattern matches, vs. standards. These putative CLN2 biomarkers include 7 acetylated species – all attenuated in CLN2 compared to controls. Because acetate is the major bioenergetic fuel for support of mitochondrial respiration, defcient acetylated species in CSF suggests a brain energy defect that may drive neurodegeneration. Targeted analysis of these metabolites in CSF of CLN2 patients ofers a powerful new approach for monitoring CLN2 disease progression and response to therapy.
    [Show full text]